WEST PALM BEACH, FLORIDA, May 19, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE:FOXO) ("FOXO" or the "Company") today announced that its critical access hospital, Big South Fork Medical Center in Oneida, Tennessee, is expanding its services by offering wound care services to patients on an inpatient and outpatient basis. The hospital intends to commence such services on June 2, 2025, and expects to complete the reconfiguration of certain space at the hospital and addition of key clinical hires to facilitate this expected start date. The hospital has experienced a growing need for wound care services particularly for diabetic patients who have wounds often characterized by excessiv

WEST PALM BEACH, FLORIDA, May 06, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE:FOXO) ("FOXO" or the "Company") today announced that its behavioral health subsidiary, Myrtle Recovery Centers, Inc., has reached key patient care milestones. Since operations commenced at its Oneida, Tennessee location in August 2023, the facility has seen over 400 patients and has served patients for over 5,000 care days. Robert Merritt, Chief of Executive Officer of Myrtle stated, "We are excited about reaching these important patient care milestones as they are indicative of the strong presence and reputation our facility has for delivering exemplary care for substance use disorder patients in East

West Palm Beach, April 29, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE:FOXO) ("FOXO" or the "Company"), today announced that effective 4.01pm Eastern Time, on April 28, 2025, (the "Effective Time"), the Company completed a 1 for 10 reverse stock split of its outstanding common stock. The Company's common stock will open for trading on Tuesday April 29, 2025, on a post-split basis and continue to trade under the symbol FOXO. As a result of the reverse split, every 10 shares of the Company's common stock issued and outstanding on the Effective Time will be consolidated into one issued and outstanding share with no change in the nominal par value per share of $0.0001. No fractional

FLORIDA, April 17, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE:FOXO) ("FOXO" or the "Company"), today announced that its Board of Directors has approved a 1 for 10 reverse stock split of the Company's Class A common stock, par value $0.0001 (the "Common Stock"). The reverse stock split will become effective at 4:01pm ET on April 28, 2025 (the "Effective Time"). The Common Stock will begin trading on a split-adjusted basis on the NYSE American under the same trading symbol "FOXO" when the market opens on April 29, 2025, and will trade under a new CUSIP number. The reverse stock split was approved by the Company's stockholders at the Company's Annual Meeting, held on November 29,

WEST PALM BEACH, FL, April 16, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the "Company") announces that it has filed its Annual Report on Form 10-K on April 15, 2025. Pursuant to the disclosure requirements of the NYSE American Company Guidelines Sections 401(h) and 610(b), FOXO is reporting that its audited financial statements for the fiscal year ended December 31, 2024, included in FOXO's Annual Report on Form 10-K filed with the Securities and Exchange Commission, contains an audit opinion from its independent registered public accounting firm that includes an explanatory paragraph related to FOXO's ability to continue as a going concern. This announcement

MINNEAPOLIS, MN, March 19, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the "Company"), announces that it has signed a non-binding agreement to acquire Vector Biosource Inc. ("Vector"). Vector is an information and biospecimen sourcing provider serving the biotechnology, clinical research and pharmaceutical research industries. Vector expects to generate $800,000 of revenues in 2025 without additional capital. The purchase price consists of: (i) $750,000 in stated value of the Company's Series D Cumulative Redeemable Preferred Stock (the "Series D Preferred Stock"), (ii) an additional $750,000 of Series D Preferred Stock subject to achieving certain agreed-upon r

MINNEAPOLIS, MN, March 12, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the "Company or FOXO"), provides an update on Myrtle Recovery Centers, Inc., ("Myrtle") and its behavioral health facility in Oneida, Tennessee, and confirms participation in a major alcohol and drug addiction conference in East Tennessee. Myrtle is pleased to announce that its Oneida, Tennessee substance abuse treatment facility has reached stabilization by maintaining an occupancy rate of 75% or greater since the beginning of 2025. In addition, on occasion, the facility has been at capacity unable to accept additional patients over the same period. Myrtle has also, since the beginning of 20

MINNEAPOLIS, MN, Feb. 24, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the "Company or FOXO"), announces that it has executed a non-binding acquisition agreement for two assisted living facilities in Florida. One facility has 129 units, and the second facility has 137 units. The purchase price for each facility is expected to be $30 million, a portion of which is milestone-based. The parties aim to complete definitive agreements withing 60 days, Closing is expected to occur between 60 and 120 days after completion of definitive agreements and is subject to a number of closing conditions, including satisfactory due diligence and financing. "We are delighted to ha

MINNEAPOLIS, MN, Jan. 28, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the "Company"), provides a brief shareholder letter from Seamus Lagan, recently appointed CEO of FOXO on what has been achieved in recent months and what is planned for 2025 and beyond. Dear Fellow Shareholders, Our recent shareholders meeting on January 17th concluded the requirements of 2024 acquisition agreements and resulted in a change of control of the Company. The accomplishments in the second half of 2024 have been key to what we believe is becoming a very successful turnaround of our Company and has created a foundation from which we believe we can build a significant and profitable

MINNEAPOLIS, MN, Jan. 16, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the "Company" or "FOXO"), will hold its previously announced Special Meeting of its Shareholders at 10:30 am EST on Friday, January 17, 2025. Following the filing of its Definitive Proxy Statement filed with the SEC on January 6, 2025, the Company is holding a virtual meeting of its shareholders (the "Special Meeting") on Friday, January 17, 2025, at 10:30 a.m. Eastern Standard Time. Shareholders of record on January 3, 2025, will be entitled to vote on the approvals requested. All shareholder votes are important. There are two ways for our shareholders to vote. Shareholders can use the inte

MINNEAPOLIS, MN, Jan. 28, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the "Company"), provides a brief shareholder letter from Seamus Lagan, recently appointed CEO of FOXO on what has been achieved in recent months and what is planned for 2025 and beyond. Dear Fellow Shareholders, Our recent shareholders meeting on January 17th concluded the requirements of 2024 acquisition agreements and resulted in a change of control of the Company. The accomplishments in the second half of 2024 have been key to what we believe is becoming a very successful turnaround of our Company and has created a foundation from which we believe we can build a significant and profitable

MINNEAPOLIS, MN, Oct. 15, 2024 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the "Company" or "FOXO"), provides a shareholder letter from Mark White, Interim CEO of FOXO, on what has been achieved in 2024 and what is planned for the remainder of 2024 and beyond. Dear Fellow Shareholders, 2024 has been an exciting, tumultuous and productive year for us. We believe the accomplishments already completed and that we believe will be achieved before year-end create a foundation from which we can build a successful enterprise that will increase shareholder value. The Company began 2024 with a continued focus on commercializing its epigenetic technology while, at the same ti

MINNEAPOLIS, MN, Sept. 17, 2024 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the "Company"), today announced it has completed the acquisition of the second revenue-generating operation from Rennova Health, Inc. (OTC:RNVA) ("Rennova").  The Company had previously announced it had entered into two share exchange agreements with Rennova. The first agreement was to acquire the equity in Myrtle Recovery Centers, Inc., Rennova's behavioral health services subsidiary. Closing of the Myrtle transaction occurred on June 14, 2024. The second agreement was to acquire the equity in Rennova Community Health, Inc. (RCHI), the owner of Scott County Community Hospital, I

MINNEAPOLIS, MN, Aug. 08, 2024 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the "Company"), today announced that its recently acquired subsidiary, Myrtle Recovery Centers, Inc. ("Myrtle"), has been granted two full licenses from the Tennessee Department of Mental Health and Substance Abuse Services, effective August 1, 2024, for 12 months. The first license authorizes the provision of services for alcohol and drug residential detoxification treatment, as well as alcohol and drug residential rehabilitation treatment. The second license authorizes the provision of services for non-residential office-based opiate treatment. FOXO completed the acquisition of Myrtle re

FOXO Technologies Inc. (NYSEAM:FOXO), a leader in the field of commercializing epigenetic biomarker technology, today reported financial results for the second quarter ended June 30, 2023. "I am very proud of our accomplishments during the second quarter," said Tyler Danielson, interim CEO and Chief Technology Officer of FOXO. "In addition to streamlining our capital structure, we continued to advance our growth initiatives through product expansion and scientific discovery. Through our partnerships with leading academic research and healthcare institutions, we are exploring new insights in longevity science and health, while at the same time developing new and exciting AI driven consumer

FOXO Technologies Inc. (NYSEAM:FOXO) ("FOXO" or the "Company"), a leader in commercializing epigenetic biomarkers of health and aging in life insurance, today reported financial results for the full year ended December 31, 2022 and accompanying business highlights. "I am truly excited with the future we are building," said Tyler Danielson, interim CEO and Chief Technology Officer of FOXO. "The challenges faced in 2022 presented us with an opportunity to take a comprehensive assessment of our business and the way we approach the market. We sought to reset our vision and mission, and identify the clear objectives that we believe are necessary to achieve them and hold ourselves accountable. O

FOXO Technologies Inc. (NYSE_AM: FOXO), a leader in commercializing epigenetic biomarkers of health and aging, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2022 after market closes on Thursday, March 30, 2023. Management will host a conference call to discuss fourth quarter and full year 2022 results and recent business highlights at 3:15 p.m. Central time on Thursday, March 30, 2023. The call can be accessed via webcast on the investors section of the Company's website at www.foxotechnologies.com/investors or by dialing (888) 770-7136 and referencing conference ID 4335886. Participants are encouraged to call in 10 to 15 min